When to Choose Aura-C™?
Detect early cancer in High risk women— even with a negative HPV test
Avoid unnecessary treatment and protect fertility️
Unclear results from Pap smear or recent changes
Monitor your health after cervical treatment
Aura-C™ Non-Invasive
Cervical Cancer Screening Process
Step 04
Laboratory TestingYour sample will be tested for early signs of cervical cancer and other abnormalities
Why Aura-C™ is a Game-Changer for Women’s Health?
Non-Invasive Sample Collection
Uses naturally shed cervical cells, so
you can get screened without
invasive procedures
DNA Methylation-Based Assay
Targets clinically validated
genetic markers (PAX1 & JAM3)
Early Detection of CIN2+ and CIN3+
Detects high-grade CIN+ (Cervical
Interepithelial Neoplasia) lesions at
early stages
High Clinical Accuracy
96.5%
89.6%
CIN2+
87.09%
95.96%
CIN3+
CE-IVD Certified
Efficient Triage Tool
Approved for clinical use.
ESMO Clinical Trials Insights
Methylation Testing in Over 10,000 Women Shows PAX1/JAM3 as Superior
Early Detection Tool for High-Risk HPV and Cervical Precancerous Lesions.
What You Receive
Gynecology Consultation
Get a personalised consultation with a
gynecologist to discuss your results
and next steps.
Further Screening or Treatment
If needed, you’ll receive recommendations
for additional screening or
treatment.
